MODIFICATION
A -- Production of Master Seeds and Pre-Licensing Serials for Foreign Animal Disease Vaccine Candidates - Amendment 1 - Amendment 2
- Notice Date
- 8/5/2010
- Notice Type
- Modification/Amendment
- NAICS
- 541711
— Research and Development in Biotechnology
- Contracting Office
- Office of the Chief Procurement Officer, Washington, District of Columbia, 20528, United States
- ZIP Code
- 20528
- Solicitation Number
- HSHQDC-10-R-00054
- Response Due
- 8/20/2010 4:00:00 PM
- Archive Date
- 9/4/2010
- Point of Contact
- Kristian Jovanovic, Phone: 202-254-6071
- E-Mail Address
-
Kristian.Jovanovic@dhs.gov
(Kristian.Jovanovic@dhs.gov)
- Small Business Set-Aside
- N/A
- Description
- New SECTION F.3 DELIVERABLES - 5 AUG 2010 New SECTION C – STATEMENT OF WORK - 5 AUG 2010 The purpose of this solicitation amendment is threefold: 1. Strike previous Request For Proposal (RFP) SECTION C - STATEMENT OF WORK in totality and replace with attached SECTION C - STATEMENT OF WORK to delineate BSL-3. (See attachment). 2. Strike previous RFP SECTION F.3 DELIVERABLES in totality and replace with attached Section F.3 DELIVERABLES, which eliminates BSL-2. (See attachment). 3. Include Government answers to industry questions. (See below). All other terms and conditions of RFP shall remain unchanged, including due date. QUESTIONS AND ANSWERS 1. "Will this follow the same timeline for de-selection from BSL3/Select Agent as the GenVec AdFMD vaccine?" Answer: The GenVec AdFMD vaccine has never been placed on the Select Agent list; therefore, there is no timeline to compare de-selection of the RFV candidate to. The ISAATTAC [Intergovernmental Select Agents and Toxins Technical Advisory Committee] issues decisions on applications for de-selection; its timelines and decisions are beyond the control of DHS and as such, DHS cannot make any claims based on the timing or certainty of decisions to de-select an agent. 2. "Will the on-going work for the GenVec AdFMD vaccine suffice to allow the de-selection of the RFV, as similar starting material and methods will be used for development?" Answer: No 3. In Base Period Milestone 1; 2.a.-c. it refers to BSL3 laboratory for production of stock, premaster, and MS marker live attenuated RVF. However, in 2.k. there is reference that the MS material may be de-selected to BSL2. The tasking and budgeting makes a huge difference from BSL2 to BSL3, both in production and maintenance of MS, but as well in manufacturing and QC. Basically, can RVF be done in BSL2 or BSL2+? It would greatly affect the budget considerations for the management of this material. Answer: No, since current requirement is BSL-3. 4. Could you tell me what cell line is used in RPF Solicitation HSHQDC-10-R-00054? Answer: Proprietary cell lines produced by GenVec, Inc. will be provided for the AdFMD work. For the RFV vaccine candidate, commercially available Vero cells can be utilized.
- Web Link
-
FBO.gov Permalink
(https://www.fbo.gov/spg/DHS/OCPO/DHS-OCPO/HSHQDC-10-R-00054/listing.html)
- Place of Performance
- Address: Plum Island Animal Disease Center, Greenport, New York, 11944, United States
- Zip Code: 11944
- Zip Code: 11944
- Record
- SN02230828-W 20100807/100805235931-2c349ffcf5484b6cb2028ef9a07fe30d (fbodaily.com)
- Source
-
FedBizOpps Link to This Notice
(may not be valid after Archive Date)
| FSG Index | This Issue's Index | Today's FBO Daily Index Page |